Pharmaceutical Fraud: The Prices, Prescriptions and Rebates Behind False Claims

Pharmaceutical fraud uses false drug-price reports, payments for prescriptions or misleading product claims to take money from public healthcare programs or keep rebates those programs are owed. The person who sees it may work nowhere near a government bill. A pricing analyst knows which discount disappeared from a calculation. A sales representative knows why a doctor received another speaking fee. A pharmacist knows why a patient’s next refill mattered to the next referral. Those decisions can explain what Medicare and Medicaid paid, and why.

What Is Pharmaceutical Fraud?

Pharmaceutical fraud is deception in drug pricing, prescribing or product claims that takes public healthcare money or keeps rebates owed to public programs.

Manufacturers supply drugs through wholesalers and pharmacies. Prescribers choose treatments. Pharmacy benefit managers negotiate with manufacturers and manage the lists of covered drugs, called formularies, for health plans. A specialty pharmacy may also handle patient support, insurance approval and refills. The business delivering the drug and the business deciding its financial terms can have different roles in the same prescription.

Drug pricing fraud can affect four public payment systems through numbers the manufacturer calculates. Average manufacturer price and Best Price, the lowest qualifying manufacturer price, determine Medicaid rebates. Average sales price drives Medicare Part B reimbursement. The 340B ceiling price draws on the Medicaid calculation. Federal purchasing, including the Department of Veterans Affairs, uses non-Federal average manufacturer price.

Under Medicare Part D, private plans administer the prescription benefit and negotiate prices and rebates. Under Part B, covered drugs commonly reach patients through physicians, outpatient departments and suppliers. Knowing which program paid tells you which price report, contract and claim matter.

What Causes Pharmaceutical Fraud?

The recurring incentive is to turn a private payment or an internal reporting decision into a larger return from public programs. A prescribing inducement generates reimbursed sales. An omitted discount shrinks a rebate bill. A payment hidden behind a service-fee label can change what Medicare gets back.

The industry’s rebate arrangements make the incentives harder to see from the invoice. Manufacturers negotiate rebates for formulary access, preferred placement and volume. Patients can face cost sharing based on the pharmacy price before those concessions reach the plan.

The USC Schaeffer Center’s 2020 paper, The Association Between Drug Rebates and List Prices, found that larger estimated rebates were associated with higher list prices. It used estimated net prices, and its rebate measure included other discounts and payments to intermediaries. The relationship was strongest where generic competition was absent:

A growing discount can accompany a growing list price. An insider with the contract and the rebate ledger can explain who actually received the concession.

How Does Pharmaceutical Fraud Reach the Government Bill?

False price reports change reimbursement and rebates. Payments to prescribers generate drug sales billed to public programs. Taxpayers fund the resulting claims while programs lose money meant for patient care.

A pharmaceutical kickback buys a prescribing, purchasing or referral decision involving federal health care business. The benefit may be a fee, a meal, free goods or access to more patients. The Anti-Kickback Statute addresses that exchange. The False Claims Act reaches resulting false payment claims.

A pricing policy, calculation and government report can show how an omitted discount changed the bill. A speaker contract, attendance sheet and prescription record can show what a payment bought. The employee who can explain why the records disagree supplies something an outside reviewer cannot read from a spreadsheet alone.

Are Pharmaceutical Companies Liable for False Claims?

Pharmaceutical companies can face False Claims Act liability for knowingly causing false claims, even when a pharmacy or physician sends the bill. They can also face claims over knowingly avoiding rebates owed to the government.

Drug approval, labeling and manufacturing obligations sit under the Food, Drug, and Cosmetic Act. Agreements between competitors over prices and customers raise antitrust questions. Our whistleblower experts work through the payment records with you and bring in pharmaceutical fraud whistleblower lawyers who know the scheme.

Who Can Be a Pharmaceutical Whistleblower?

Employees, pharmacists, physicians and businesses have brought pharmaceutical whistleblower cases. The useful contribution is knowledge of the transaction: what was promised, what happened, what was reported and who understood the difference.

A pricing analyst may see a wholesaler fee deducted in the wrong calculation. Sales and medical-affairs employees may know who selected the paid speakers and what the presentations actually said. A pharmacy employee may see refill targets, referral allocations and counseling instructions together. Compliance and regulatory employees may know that an internal warning contradicted a later certification.

Ven-A-Care, a home-infusion pharmacy, brought average-wholesale-price cases from its position in the supply chain. Its purchasing experience put it close to the difference between the price a pharmacy paid and the benchmark used for reimbursement. The insider can be the customer who knows the transaction just as well as the employee who prepared it.

What Evidence Is Needed to Prove Fraud?

The strongest pharmaceutical fraud evidence connects the commercial arrangement to the government claim or rebate obligation. Contracts describe the deal. Invoices, rebates and payment files show its economics. Calculation files show what went into the reported price. Emails, audit findings and corrections can explain what the company knew when it submitted the next report.

For prescribing schemes, the corresponding comparison is between the service described and the activity delivered. Attendance records, presentation materials, expenses and prescription tracking can expose an event built around paying the prescriber. Open Payments can identify a reported transfer. The purpose of the payment and its connection to prescriptions come from the surrounding evidence.

How Do You Report Pharmaceutical Fraud?

Start with our whistleblower experts to discuss how to report pharmaceutical fraud through a case grounded in the transactions you know. Questions about confidentiality, your role or earlier disclosures belong in that conversation, because we work through them with you.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

Pharmaceutical Fraud Schemes and the Records Behind Them

Pharmaceutical fraud cases recur around the same decisions: which price to report, which prescription to reward and which payment to disclose. The examples below show where those decisions leave evidence.

Medicaid Best Price Fraud and Bundled Discounts

Medicaid Best Price fraud allegations produced a $784.6 million settlement with Wyeth and Pfizer in 2016. The Justice Department alleged that Wyeth bundled discounts on oral and intravenous Protonix to win hospital business but left those discounts out of Best Price. The hospital got the deal. Medicaid’s rebate calculation did not.

The underlying sales agreement matters because a discount can sit on another product in the bundle. Best Price includes qualifying rebates, volume discounts and contingent free goods. Discounts on a bundle must be spread across its products.

Drug Misclassification and Inflation Rebates

Drug misclassification allegations led to Mylan‘s $465 million settlement in 2017. The government alleged that Mylan reported EpiPen as a generic to reduce Medicaid rebates while raising its private-market price.

Base-date AMP manipulation accounted for approximately $234.7 million of Mallinckrodt‘s 2022 settlement. The government alleged that treating Acthar as newly marketed reset its pricing history and avoided inflation rebates on earlier increases. Mallinckrodt admitted the drug was not new and agreed to correct the base date.

Average Manufacturer Price and Average Sales Price Service Fees

Average manufacturer price misreporting allegations led Cephalon to a $7.5 million settlement in 2015 over improper wholesaler-fee deductions. Treating a real service fee as a discount can lower AMP and the Medicaid rebate.

Average sales price fraud can reverse that incentive. Average sales price reflects sales after discounts. Calling a real discount a service fee can leave ASP, and Medicare Part B reimbursement, too high.

The actual service, its value and whether the payment reached a customer matter more than the ledger’s description.

Average Wholesale Price and Compounding

Average wholesale price fraud allegedly caused hundreds of millions of dollars in excess TRICARE reimbursement in the government’s 2021 complaint against PCCA. Average wholesale price is a published benchmark. The Justice Department alleged that the ingredient supplier inflated it, promoted the resulting pharmacy profits and designed compound-drug formulas to maximize reimbursement.

An ingredient’s purchase invoice, published benchmark and recommended formula can explain why that ingredient entered the prescription. The reimbursement pitch is part of the product being sold.

Pharmacy Benefit Manager Fraud and Part D Rebates

Part D rebate reporting fraud allegations led Rite Aid and Elixir to agree to a $101 million payment in 2024. The Justice Department alleged that retained manufacturer rebates were reported as service fees even though manufacturers had not negotiated those fees. That treatment affected Medicare’s reconciliation of payments.

For PBM fraud and drug rebates, the contract and the report have to be read together. Affiliate payments and rebate-aggregator arrangements make the identity of the recipient part of the inquiry.

Speaker Programs and Consulting Payments

Speaker program kickbacks led to approximately $591 million in federal False Claims Act damages in Novartis‘s 2020 settlement. Novartis admitted prescribing inducements, repeated dinners and events that never happened. A sales representative used fake restaurant receipts to buy gift cards for high-prescribing doctors.

The invitation list, attendance records and expenses show what the program actually purchased. For consulting, advisory boards and research payments, the work promised and the work delivered tell the same story.

Copay Charity Kickbacks

Copay charity kickbacks allegations led to Teva‘s $425 million civil settlement in 2024. The government alleged that Teva worked with a specialty pharmacy to direct foundation funding to Copaxone patients while raising the drug’s price.

The fund’s eligibility rules, application timing and data returned to a donor can connect a charitable contribution to the manufacturer’s own sales.

Specialty Pharmacy Referrals and Drug Switching

Specialty pharmacy kickbacks tied 60% of undesignated Exjade referrals to the highest refill score, Accredo admitted. Accredo admitted that the score counted how long patients kept ordering refills, without excluding patients who stopped because of side effects or a physician’s direction.

The measure rewarded continued ordering even when the reason for stopping was medical. For pharmacy staff, the referral scorecard explains why a refill call could carry a commercial target.

Drug switching can follow the same incentive. In the Myfortic allegations, the government said Novartis offered pharmacy rebates in exchange for recommendations that doctors move patients from competing drugs.

Free Samples and Diagnostic Testing

Free drug samples billed to Medicare figured in the criminal indictment of TAP Pharmaceutical Products managers. The indictment charged that they caused Medicare billings for thousands of free Lupron samples. Separately, TAP’s $585 million civil resolution in 2001 addressed inflated price reporting, marketing the reimbursement spread and Medicaid Best Price allegations.

Free testing can generate the prescription itself. QOL Medical and its chief executive agreed to a $47 million civil settlement in 2024. QOL admitted providing free breath tests, obtaining results, directing sales calls to providers with positive results and tracking conversion into Sucraid prescriptions.

The whistleblowers’ complaint alleged how staff were told to handle questions about the test:

False Prior Authorizations and Unnecessary Refills

False prior authorizations put invented patient information into the coverage decision. In the whistleblower’s complaint against kaléo and pharmacies including Solera Specialty Pharmacy, the whistleblower alleged that a network pharmacy claimed patients were blind to obtain Medicare coverage. The complaint also described a push for replacement prescriptions while patients still held usable, unexpired doses.

Walgreens agreed to a settlement over allegations that it billed public programs for prescriptions patients never picked up. Dispensing records and reversed claims can show whether a paid prescription ever reached the patient.

What Is Considered Off-Label Promotion?

Off-label promotion promotes a drug for a use beyond its FDA-approved labeling. Off-label promotion allegations led to AstraZeneca‘s $520 million civil settlement in 2010.

Medical compendia, the reference works used in coverage decisions, can support payment for uses beyond the approved label. That makes the evidence behind a listing commercially important.

The government alleged that AstraZeneca recruited doctors to put their names on ghostwritten articles about studies they had not conducted, then used those articles to promote unapproved uses of Seroquel.

Clinical-trial data can also conceal a failed result. In its guilty plea, GlaxoSmithKline admitted misreporting a Paxil trial as showing efficacy and withholding other failed study results. It also admitted failing to report Avandia safety data to FDA.

Manufacturing Quality and False Test Data

Manufacturing-quality allegations led to a $350 million civil settlement in the Ranbaxy case in 2013. The Justice Department described claims for drugs produced at the Paonta Sahib and Dewas facilities. Separately, in its guilty plea, Ranbaxy USA admitted conduct involving adulterated drugs and false statements to FDA, including stability-test dates.

For someone inside quality control, the underlying tests and the statements sent to the regulator are the critical comparison.

340B Discounts and Manufacturer Overcharges

340B fraud and overcharging can arise at different sides of a discounted purchase. False manufacturer price inputs can affect the ceiling paid by eligible providers. Diversion concerns discounted drugs reaching people outside the covered entity’s patient population.

Duplicate discounts concern the same drug receiving both the 340B discount and a Medicaid rebate. The Health Resources and Services Administration’s duplicate-discount guidance describes the prohibition and the covered entity’s responsibility to prevent it. Purchase records, patient eligibility and Medicaid billing identify which transaction is at issue.

Generic Drug Price Fixing

Generic drug price fixing allegations led to Teva’s separate $25 million False Claims Act settlement in 2024. The government alleged that agreements with competitors over prices and customers led to false claims on public health programs.

For an employee handling bids or customer accounts, communications with a competitor may explain a price or allocation that the ordinary sales record cannot.

You Know Why the Numbers Changed

If you can explain the discount, speaker payment, refill target or test result behind a public drug bill, speak with our pharmaceutical whistleblower experts. We build the case strategy with you, bring in pharmaceutical fraud whistleblower lawyers who know drug-pricing and kickback cases, and remain your partners throughout the case.